Treatment of primary cutaneous lichenoid amyloidosis with abrocitinib: A pilot study in two cases.

International Journal of DermatologyEarly View Correspondence Treatment of primary cutaneous lichenoid amyloidosis with abrocitinib: A pilot study in two cases Juan Bai MD, Juan Bai MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorWang Su MD, Wang Su MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHong Fang MD, Corresponding Author Hong Fang MD [email protected] Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorJianjun Qiao MD, PhD, Corresponding Author Jianjun Qiao MD, PhD [email protected] orcid.org/0000-0003-3386-297X Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this author Juan Bai MD, Juan Bai MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorWang Su MD, Wang Su MD Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHong Fang MD, Corresponding Author Hong Fang MD [email protected] Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorJianjun Qiao MD, PhD, Corresponding Author Jianjun Qiao MD, PhD [email protected] orcid.org/0000-0003-3386-297X Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this author First published: 25 April 2023 https://doi.org/10.1111/ijd.16698 Conflict of interest: None. Funding source: Health science and Technology Project fo Health commission of Zhejiang Province (2023KY102). Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Aung T, Noakes R, Murrell DF, Daniel BS, Kelati A. Primary cutaneous amyloidosis: a review of the available studies and gaps in data. Australas J Dermatol. 2023. [Epub ahead of print]. https://doi.org/10.1111/ajd.14012 2Fakhraie S, Daftary K, Venkatesh S, Chovatiya R. Lichen amyloidosis: towards pathogenesis-driven targeted treatment. Clin Exp Dermatol. 2023; 48(3): 261– 2. 3Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part II. A comprehensive review. J Am Acad Dermatol. 2022; 86(2): 414– 22. 4Tey HL, Cao T, Nattkemper LA, Tan VW, Pramono ZA, Yosipovitch G. Pathophysiology of pruritus in primary localized cutaneous amyloidosis. Br J Dermatol. 2016; 174(6): 1345– 50. 5Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017; 171(1): 217– 228.e13. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation